Roche Enters the Clinical Mass Spectrometry Market with Integrated High-Throughput System

Research and analytical instruments are an important cornerstone of the life sciences and pharmaceuticals industry, among which mass spectrometers represent one of the main fields with the largest market share, the highest average price, and the greatest technical barriers.2021 Global Mass Spectrometry Market in [Year] Approximately450100 million yuan, expected2026 Global Mass Spectrometer Market Size Reachable by Year700 100 million yuan.2021 China's mass spectrometer market in year150 billion yuan, accounting for the global market30%, Localization rate approximately10%。Expected2025 In 2023, the clinical mass spectrometer market in China is approximately24 100 million yuan

With the development of precision medicine, the demand for clinical precision testing continues to expand. Mass spectrometry technology, with its unique advantages such as high sensitivity, high specificity, and multi-parameter detection, has become a highly promising new technology in in vitro diagnostics, providing a new direction for the advancement of precision medicine.

2021The market size of clinical mass spectrometry for newborn genetic metabolic diseases in China is approximately17.20Hundreds of millions, the microbiological testing market is approximately20.5100 million yuan,TDMMarket Size in38.55Hundreds of millions, the scale of microbial testing is approximately17.54100 million yuan, in summary2021Breakthrough in China's Clinical Mass Spectrometry Testing Market100100 million yuan. With the relaxation of policies, hospitals and third-party medical testing institutions have begun to develop.LDTThe number of projects will also increase. Meanwhile, with the relaxation of the three-child policy and the acceleration of aging in China, the demand for screening of corresponding genetic diseases, early tumor screening, and precision medicine will continue to grow.

Self2012Since the year, approximately25Chinese mass spectrometry companies have completed approximately74Round of financing, with an amount exceeding23Hundreds of millions, in recent years both the number of financings and the scale of financing have far exceeded those of previous years. Additionally, the scale of financing also surpasses that of others.IVDManufacturers are eagerly awaiting.2022In 2023, Chinese clinical mass spectrometry companies raised over10Hundreds of millions, including multiple financing events at the hundred-million level.

In the past two years, with the rapid development of the clinical mass spectrometry industry, the number of enterprises entering the track has been increasing. In this emerging golden track, in vitro diagnostic giants are rushing to enter the market, while traditional scientific instrument manufacturers are accelerating their catch-up. In the middle of the track, there is also a group of upstart companies that focus on the manufacturing of mass spectrometers and concentrate on medical diagnostic applications. It can be said that,The investment enthusiasm and financing amount in the clinical mass spectrometry industry have significantly increased, gradually revealing its potential to become the next golden track in the precision medicine field.